-
Haisco: IND application for new indications for HSK21542 injection has been accepted
Time of Update: 2021-06-01
HSK21542 injection (hereinafter referred to as "HSK21542") is a brand-new analgesic drug with independent intellectual property rights developed by Haisco.
According to my country's new chemical drug registration classification regulations, its drug registration is classified as chemical drugs.
-
Transforming county market CSO?
Time of Update: 2021-06-01
According to the cooperation content, this cooperation with AstraZeneca is mainly responsible for promoting the expansion of bevacizumab injection to the domestic county market.
It is worth noting that this cooperation is not the first domestic market promotion right that AstraZeneca won in the first half of this year.
-
The Food and Drug Administration issued an announcement on the supplementary inspection method for the pseudo-ginsenoside F11 inspection item in Ginseng Yangrong Pills
Time of Update: 2021-06-01
On May 25, the State Food and Drug Administration issued a supplementary test method for the F11 check item of pseudo-ginsenosides in Ginseng Yangrong Pills, a supplementary test method for check item
-
Phase 3 clinical results of innovative peptide-conjugated drugs for the treatment of multiple myeloma are positive
Time of Update: 2021-06-01
On May 25, 2021, Oncopeptides AB announced that its peptide-conjugated drug Pepaxto (melphalan flufenamide) has achieved positive results in a phase 3 clinical trial for the treatment of relapsed/refractory multiple myeloma (R/R MM).
-
Johnson & Johnson's EGFR/c-Met dual antibody, the first new drug for specific mutations in lung cancer, was approved by the FDA for marketing
Time of Update: 2021-06-01
On May 21, the FDA issued an announcement to accelerate the approval of Johnson & Johnson's Rybrevant (amivantamab-vmjw) for patients with metastatic non-small cell lung cancer (NSCLC) who have advanced EGFR exon 20 insertion mutations after platinum-based chemotherapy.
-
Yangtze River won 5 blockbuster new products in one fell swoop to impact Renfu's exclusive painkillers
Time of Update: 2021-06-01
Recently, Yangtze River’s product pipeline has been continuously updated: 3 types of generic drug nalbuphine hydrochloride injection have entered the administrative approval stage, and this product is currently only sold by Renfu; 5 generic drugs have been approved for marketing, and 4 of them have been approved for production and deemed to have been used.
-
11 medicines are higher than the lowest prices in the five provinces and cities to withdraw from the Internet soon!
Time of Update: 2021-06-01
The price is higher than the lowest price in the five provinces and cities, and the companies involved include Jianlang Pharmaceutical, Jichuan Pharmaceutical, Wanle Pharmaceutical, Jinyuan Pharmaceutical, Baiyunshan Pharmaceutical General Factory, and Pfizer.
-
Bayer's heart failure drug Verquvo is recommended by the EU CHMP and approved by China to enter the review
Time of Update: 2021-06-01
Data show that when used in combination with available heart failure drugs, compared with placebo, the once-daily 10 mg dose of vericiguat significantly reduces the relative risk of the composite endpoint of heart failure hospitalization and cardiovascular death after a worsening event by 10% (HR=0.
-
Big variety of 5 billion injections, Beite, Poinsettia...4 reviews on the same day
Time of Update: 2021-06-01
Figure 2: The share of TOP5 companies in Omeprazole Sodium for Injection in 2020 Source: Mi Nei. com, China's public medical institutions terminal competition pattern In 2020, in China's public medical institutions, Osaikon will occupy more than 40% of the market share of Omeprazole Sodium for injection.
-
Type 1 diabetes antibody drug teplizumab is supported by the U.S. FDA Advisory Committee
Time of Update: 2021-06-01
In clinical trials supporting the drug NDA, a 2-week course of teplizumab treatment can delay the onset of type 1 diabetes by an average of 2 years.
-
77 medical device industry standards will be revised!
Time of Update: 2021-06-01
Medical Network, May 28 News On May 26, the State Food and Drug Administration issued the "2021 Medical Device Industry Standards Establishment and Revision Plan Project Publicity", which determined
-
Ge Junbo: Keep a bit naive, that is the driving force for innovation
Time of Update: 2021-05-31
The “last bastion” of interventional treatment of coronary artery disease; he led the team for more than ten years of continuous research and developed the first fully biodegradable stent in China which was approved for listing last year; he initiated the doctor innovation club to gather national innovation forces for China Medical has injected more "hard core power.
-
2 new local confirmed cases in 31 provinces, regions and cities in Anhui
Time of Update: 2021-05-31
As of 24:00 on May 24, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 319 confirmed cases (including 3 severe cases), a total of 86,051 cured and discharged cases, and a total of 4,636 deaths.
-
The mutant strain reminds us that we must race against time!
Time of Update: 2021-05-31
my country's new crown vaccination shows "acceleration" mutant strains remind us that we must race against time!
my country's new crown vaccination shows "acceleration" mutant strains remind us that we must race against time!
-
The community transmission chain of the Yingkou epidemic has been basically blocked
Time of Update: 2021-05-31
At present, 520,000 people in Bayuquan District, Yingkou City have completed the third round of full-staff nucleic acid tests, and the results are all negative.
-
The leader of infectious diseases in China: 68 years of continuous search for patients with heart
Time of Update: 2021-05-31
In order to make the patients with bacterial infections "available", in 1963, the state decided to establish the "Shanghai First Medical College Antibiotics Clinical Application Research Laboratory" in Huashan Hospital to conduct clinical evaluations of my country's first batch of self-developed new antibacterial drugs.
-
Health Commission: 19 new confirmed cases and 2 local cases
Time of Update: 2021-05-31
The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on May 26 The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on May 26 The lat
-
Finland's research and development of nasal spray new crown medicament obtained patent
Time of Update: 2021-05-31
" In a telephone interview with Xinhua News Agency, the main developer of the new drug, Carlylvo Vernell, said that because the principle of the nasal spray is to target the human body rather than the virus, the mutant virus has little effect on its efficacy.
-
congratulate!
Time of Update: 2021-05-31
Chinese aid Hubei expert Wu Hao won the Sasakawa Health Award congratulate!
Congratulations on Chinese aid Hubei expert Wu Hao for winning the Sasakawa Health Award!
The national health administration departments of WHO member states and past winners can propose candidates, and the decision will be made by the World Health Organization Executive Committee.
-
There is no mutated new coronavirus that poses a substantial threat to existing vaccines
Time of Update: 2021-05-31
When talking about the global new crown epidemic situation at the opening ceremony of the conference, World Health Organization Director-General Tan Desai said that so far, there has not been a mutated new crown virus that can seriously damage the effectiveness of existing vaccines, diagnoses or treatments.
